Prothena spins out of Elan
This article was originally published in Scrip
Elan has carried out the demerger of its drug discovery activities into a new company, which it has named Prothena. The operation, which the firm announced back in August when its Phase III Alzheimer's antibody, intravenous bapineuzumab, partnered with Janssen and Pfizer, failed in a pivotal trial, conducted by Janssen (scripintelligence.com, 7 August 2012, 13 August 2012 and 15 August 2012).
You may also be interested in...
In the backlash following the failure of its late-stage amyloidosis drug, Prothena has announced it will cut 57% of its workforce as part of a restructuring plan.
Prothena CEO Dale Schenk, the scientist behind innovative medicines that included bapineuzumab and Tysabri, died from pancreatic cancer on Sept. 30 – less than two years after he revealed his diagnosis.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.